BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Director Sells $1,825,200.00 in Stock

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) Director Jean Jacques Bienaime sold 20,000 shares of the company's stock in a transaction on Friday, April 12th. The stock was sold at an average price of $91.26, for a total transaction of $1,825,200.00. Following the transaction, the director now owns 474,994 shares in the company, valued at approximately $43,347,952.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Jean Jacques Bienaime also recently made the following trade(s):

• On Tuesday, March 5th, Jean Jacques Bienaime sold 1,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $85.51, for a total transaction of $85,510.00.
• On Tuesday, February 27th, Jean Jacques Bienaime sold 1,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $90.35, for a total transaction of $90,350.00.
• On Friday, February 9th, Jean Jacques Bienaime sold 15,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $88.28, for a total transaction of $1,324,200.00.

BioMarin Pharmaceutical Stock Performance

NASDAQ:BMRN traded down $0.71 on Monday, reaching $91.51. 1,942,193 shares of the company's stock were exchanged, compared to its average volume of 1,356,714. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.51 and a quick ratio of 1.57. The firm has a market cap of $17.27 billion, a price-to-earnings ratio of 103.99, a P/E/G ratio of 1.76 and a beta of 0.31. BioMarin Pharmaceutical Inc. has a 52 week low of $76.02 and a 52 week high of $100.38. The stock has a fifty day simple moving average of $87.53 and a 200-day simple moving average of $89.08.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last issued its earnings results on Thursday, February 22nd. The biotechnology company reported $0.49 earnings per share for the quarter, topping analysts' consensus estimates of $0.44 by $0.05. The firm had revenue of $646.21 million during the quarter, compared to analyst estimates of $639.53 million. BioMarin Pharmaceutical had a net margin of 6.93% and a return on equity of 5.01%. The company's quarterly revenue was up 20.2% on a year-over-year basis. During the same quarter last year, the business earned $0.11 earnings per share. As a group, sell-side analysts predict that BioMarin Pharmaceutical Inc. will post 1.93 earnings per share for the current year.

Institutional Investors Weigh In On BioMarin Pharmaceutical

A number of institutional investors and hedge funds have recently modified their holdings of the company. Stratos Wealth Partners LTD. lifted its holdings in shares of BioMarin Pharmaceutical by 2.1% in the fourth quarter. Stratos Wealth Partners LTD. now owns 5,709 shares of the biotechnology company's stock worth $550,000 after buying an additional 115 shares in the last quarter. CWM LLC lifted its holdings in shares of BioMarin Pharmaceutical by 10.0% in the third quarter. CWM LLC now owns 1,301 shares of the biotechnology company's stock worth $115,000 after buying an additional 118 shares in the last quarter. KB Financial Partners LLC lifted its holdings in shares of BioMarin Pharmaceutical by 51.3% in the third quarter. KB Financial Partners LLC now owns 348 shares of the biotechnology company's stock worth $31,000 after buying an additional 118 shares in the last quarter. Virtus ETF Advisers LLC lifted its holdings in shares of BioMarin Pharmaceutical by 3.8% in the fourth quarter. Virtus ETF Advisers LLC now owns 3,342 shares of the biotechnology company's stock worth $322,000 after buying an additional 121 shares in the last quarter. Finally, Howe & Rusling Inc. lifted its holdings in shares of BioMarin Pharmaceutical by 0.4% in the fourth quarter. Howe & Rusling Inc. now owns 36,279 shares of the biotechnology company's stock worth $3,755,000 after buying an additional 128 shares in the last quarter. 98.71% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on BMRN. Cantor Fitzgerald reiterated an "overweight" rating and issued a $100.00 target price on shares of BioMarin Pharmaceutical in a research note on Friday, February 23rd. Robert W. Baird reduced their target price on shares of BioMarin Pharmaceutical from $127.00 to $104.00 and set an "outperform" rating for the company in a research note on Tuesday, January 30th. Canaccord Genuity Group reiterated a "hold" rating and issued a $91.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday, February 29th. Stifel Nicolaus reiterated a "buy" rating and issued a $101.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday, December 21st. Finally, Piper Sandler reduced their target price on shares of BioMarin Pharmaceutical from $115.00 to $107.00 and set an "overweight" rating for the company in a research note on Friday, February 23rd. Seven investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat, BioMarin Pharmaceutical presently has a consensus rating of "Moderate Buy" and a consensus price target of $107.61.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.